Clinical Trial Update: A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase II, single-center trial is evaluating the combination of sacituzumab tirumotecan with tagitanlimab as neoadjuvant therapy for PD-L1-positive, resectable…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)
• Tagitanlimab

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Resectable Stage II-IIIB NSCLC | Phase 2 | Status: NOT_YET_RECRUITING